Identifying Patients with Polycythemia Vera at Risk of Thrombosis after Hydroxyurea Initiation: The Polycythemia Vera-Advanced Integrated Models (PV-AIM) Project.

biomarkers hydroxyurea machine learning polycythemia vera real-world evidence ruxolitinib thromboembolic events

Journal

Biomedicines
ISSN: 2227-9059
Titre abrégé: Biomedicines
Pays: Switzerland
ID NLM: 101691304

Informations de publication

Date de publication:
07 Jul 2023
Historique:
received: 09 05 2023
revised: 13 06 2023
accepted: 22 06 2023
medline: 29 7 2023
pubmed: 29 7 2023
entrez: 29 7 2023
Statut: epublish

Résumé

Patients with polycythemia vera (PV) are at significant risk of thromboembolic events (TE). The PV-AIM study used the Optum

Identifiants

pubmed: 37509564
pii: biomedicines11071925
doi: 10.3390/biomedicines11071925
pmc: PMC10377437
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Novartis Pharma AG
ID : x

Références

Am Fam Physician. 2021 Jun 1;103(11):680-687
pubmed: 34060791
Blood Cells Mol Dis. 2020 Feb;80:102368
pubmed: 31669934
J Clin Oncol. 2023 Jul 1;41(19):3534-3544
pubmed: 37126762
J Blood Med. 2019 Nov 14;10:381-390
pubmed: 31814788
Blood Cancer J. 2018 Nov 12;8(11):112
pubmed: 30420642
Haematologica. 2017 Jan;102(1):103-109
pubmed: 27686377
N Engl J Med. 2015 Jan 29;372(5):426-35
pubmed: 25629741
Cancer. 2022 Jul 1;128(13):2441-2448
pubmed: 35417564
Blood Coagul Fibrinolysis. 2016 Sep;27(6):648-52
pubmed: 26569516
Am J Hematol. 2015 May;90(5):422-8
pubmed: 25691355
Br J Haematol. 2019 Jan;184(2):176-191
pubmed: 30478826
Leukemia. 2012 Apr;26(4):563-71
pubmed: 22076463
Lancet Haematol. 2020 Mar;7(3):e226-e237
pubmed: 31982039
Ann Hematol. 2019 May;98(5):1071-1082
pubmed: 30848334
Clin Adv Hematol Oncol. 2017 Nov;15(11):848-850
pubmed: 29200417
Br J Haematol. 2016 Mar;172(5):786-93
pubmed: 26898196
Clin Lymphoma Myeloma Leuk. 2020 Feb;20(2):63-69
pubmed: 31865003
Blood. 2015 Jul 23;126(4):560-1
pubmed: 26206947
Blood Adv. 2019 Jun 11;3(11):1729-1737
pubmed: 31175128
Oncol Res Treat. 2020;43(10):526-530
pubmed: 32772025
Front Oncol. 2019 Nov 07;9:1186
pubmed: 31788449
Leukemia. 2013 Sep;27(9):1874-81
pubmed: 23739289
Lancet Oncol. 2017 Jan;18(1):88-99
pubmed: 27916398
Am J Hematol. 2022 Feb 1;97(2):E35-E37
pubmed: 34822188
Blood Cancer J. 2022 Feb 10;12(2):28
pubmed: 35145055
Lancet Haematol. 2020 Jul;7(7):e541-e550
pubmed: 32589980
Leukemia. 2022 Feb;36(2):566-568
pubmed: 34497324
Br J Haematol. 2021 Jan;192(2):239-250
pubmed: 32602593
Blood. 2016 May 19;127(20):2391-405
pubmed: 27069254
Leukemia. 2021 Feb;35(2):623-627
pubmed: 32372025
J Int Med Res. 2019 Jul;47(7):3099-3108
pubmed: 31167586
N Engl J Med. 2013 Jan 3;368(1):22-33
pubmed: 23216616
Am J Hematol. 2017 Jan;92(1):E5-E6
pubmed: 27737508
N Engl J Med. 2017 Jun 1;376(22):2168-2181
pubmed: 28564565
Haematologica. 2019 Dec;104(12):2391-2399
pubmed: 31123026
Blood Adv. 2020 Jan 28;4(2):380-386
pubmed: 31985808

Auteurs

Srdan Verstovsek (S)

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

Ivan Krečak (I)

Department of Internal Medicine, General Hospital of Sibenik-Knin County, 22000 Sibenik, Croatia.
Faculty of Medicine, University of Rijeka, 51000 Rijeka, Croatia.

Florian H Heidel (FH)

Hematology, Oncology, Stem Cell Transplantation and Palliative Care, Internal Medicine C, University Medicine Greifswald, 17475 Greifswald, Germany.

Valerio De Stefano (V)

Sezione di Ematologia, Dipartimento di Scienze Radiologiche ed Ematologiche, Università Cattolica, Fondazione Policlinico A. Gemelli IRCCS, 00168 Roma, Italy.

Kenneth Bryan (K)

Novartis Ireland Limited, Dublin 4, D04 A9N6 Dublin, Ireland.

Mike W Zuurman (MW)

Novartis Pharma AG, CH-4056 Basel, Switzerland.

Michael Zaiac (M)

Novartis Pharma AG, CH-4056 Basel, Switzerland.

Mara Morelli (M)

Novartis Farma SpA, 21040 Origgio, Italy.

Aoife Smyth (A)

Novartis Pharma AG, CH-4056 Basel, Switzerland.
Novartis Pharmaceuticals UK Limited, London W12 7FQ, UK.

Santiago Redondo (S)

Novartis Farmaceutica, S.A., 28033 Madrid, Spain.

Erwan Bigan (E)

The Boston Consulting Group, Boston, MA 02210, USA.

Michael Ruhl (M)

The Boston Consulting Group, Boston, MA 02210, USA.

Christoph Meier (C)

The Boston Consulting Group, Boston, MA 02210, USA.

Magali Beffy (M)

The Boston Consulting Group, Boston, MA 02210, USA.

Jean-Jacques Kiladjian (JJ)

Centre d'Investigations Cliniques (INSERM CIC 1427), Université de Paris, Hôpital Saint-Louis, AP-HP, 75010 Paris, France.

Classifications MeSH